glp-1 agonists quizlet Emerging Role of Dual and GIP Receptor | DMSO GLP-1 receptor agonists for individualized

Currently, two ongoing clinical trials are investigating the role of GLP-1 RAs in IBD management, that would lead to further knowledge: a French study (ID NCT05196958) evaluating the safety and efficacy of GLP-1 RAs in treatment of DM2 in overweight IBD patients (115), and an American study (ID NCT06774079) comparing the efficacy of GLP-1 RAs tirzepatide versus diet in CD patients (116)

The symptoms persisted for a median duration of 47 days in people with obesity on GLP-1 RA therapy [18], which may be ascribed to the more chronic nature of the condition [35]

2024;47(Suppl 1):S14557

The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone

But the medication effect typically depends on continuing the medication